Padeliporfin is a medication used to treat men with prostate cancer. Padeliporfin used as a photosensitiser for photodynamic therapy. Padeliporfin was developed by Yeda Research And Development Co. Ltd..
The API has now reached off-patent status, after being launched in 2017.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Padeliporfin and many others, contact info@pharmacheminvestor.com